Financials data is unavailable for this security.
View more
Year on year Egetis Therapeutics AB (publ) had net income fall 68.58% from a loss of 193.80m to a larger loss of 326.70m despite revenues that grew 154.87% from 22.60m to 57.60m over the same period.
Gross margin | 92.12% |
---|---|
Net profit margin | -224.92% |
Operating margin | -218.21% |
Return on assets | -33.65% |
---|---|
Return on equity | -62.24% |
Return on investment | -40.07% |
More ▼
Cash flow in SEKView more
In 2023, Egetis Therapeutics AB (publ) increased its cash reserves by 137.51%, or 175.60m. Cash Flow from Financing totalled 458.90m or 796.70% of revenues. In addition the company used 278.40m for operations while cash from investing was breakeven.
Cash flow per share | -0.7049 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.37 |
---|---|
Tangible book value per share | -0.0243 |
More ▼
Balance sheet in SEKView more
Current ratio | 1.56 |
---|---|
Quick ratio | 1.55 |
Total debt/total equity | 0.2752 |
---|---|
Total debt/total capital | 0.2158 |
More ▼